首页 > 最新文献

Aging Male最新文献

英文 中文
Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism. PDE5 抑制剂对伴有或不伴有性腺功能减退症的中老年患者的疗效和安全性。
IF 2.6 4区 医学 Q2 Medicine Pub Date : 2024-12-01 Epub Date: 2023-12-26 DOI: 10.1080/13685538.2023.2288347
Chunlin Wang, Hui Zhang, Fu Wang, Jun Guo, Jianlin Yuan, Guangdong Hou, Ming Gao, Zheng Li, Yan Zhang

Purpose: Although several reviews have evaluated the use of PDE5 inhibitors (PDE5i) for treating erectile dysfunction (ED), their specific use in middle-aged and old patients has not been fully evaluated. Given that elderly patients with ED often have a complex combination of systemic and sexual health risk factors, the safety and efficacy of PDE5i in such a context are hereby reviewed.

Materials and methods: A thorough examination of existing literature has been conducted on PubMed.

Results: PDE5i has good safety and efficacy, but the situation is more complex for patients with hypogonadism than those with normal testosterone levels, with reduced responsiveness to PDE5i. In this case, combination therapy with testosterone is recommended, safe and effective.

Conclusions: Eliminating or reducing reversible risk factors and controlling or slowing the development of irreversible factors is an important foundation for using PDE5i to treat ED in all patients, especially middle-aged and elderly ones.

目的:尽管已有多篇综述对使用PDE5抑制剂(PDE5i)治疗勃起功能障碍(ED)进行了评估,但尚未对其在中老年患者中的具体应用进行全面评估。鉴于患有 ED 的老年患者通常具有复杂的全身性和性健康风险因素组合,本文对 PDE5i 在这种情况下的安全性和有效性进行了综述:结果:PDE5i 具有良好的安全性和有效性:PDE5i具有良好的安全性和有效性,但性腺功能减退症患者的情况比睾酮水平正常的患者更为复杂,他们对PDE5i的反应性降低。在这种情况下,建议与睾酮联合治疗,既安全又有效:消除或减少可逆的危险因素,控制或减缓不可逆因素的发展,是使用PDE5i治疗所有患者(尤其是中老年患者)ED的重要基础。
{"title":"Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism.","authors":"Chunlin Wang, Hui Zhang, Fu Wang, Jun Guo, Jianlin Yuan, Guangdong Hou, Ming Gao, Zheng Li, Yan Zhang","doi":"10.1080/13685538.2023.2288347","DOIUrl":"10.1080/13685538.2023.2288347","url":null,"abstract":"<p><strong>Purpose: </strong>Although several reviews have evaluated the use of PDE5 inhibitors (PDE5i) for treating erectile dysfunction (ED), their specific use in middle-aged and old patients has not been fully evaluated. Given that elderly patients with ED often have a complex combination of systemic and sexual health risk factors, the safety and efficacy of PDE5i in such a context are hereby reviewed.</p><p><strong>Materials and methods: </strong>A thorough examination of existing literature has been conducted on PubMed.</p><p><strong>Results: </strong>PDE5i has good safety and efficacy, but the situation is more complex for patients with hypogonadism than those with normal testosterone levels, with reduced responsiveness to PDE5i. In this case, combination therapy with testosterone is recommended, safe and effective.</p><p><strong>Conclusions: </strong>Eliminating or reducing reversible risk factors and controlling or slowing the development of irreversible factors is an important foundation for using PDE5i to treat ED in all patients, especially middle-aged and elderly ones.</p>","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139038163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erectile dysfunction in patient with obstructive sleep apnea: effects of continuous positive airway pressure. 阻塞性睡眠呼吸暂停患者的勃起功能障碍:持续气道正压的影响。
IF 2.6 4区 医学 Q2 Medicine Pub Date : 2024-12-01 Epub Date: 2024-02-22 DOI: 10.1080/13685538.2024.2317165
Hyeyun Kim, Keun Tae Kim, Won Chul Shin, Kwang Ik Yang, Ji Yong Ha, Yong Won Cho

Background: Obstructive sleep apnea (OSA) is linked to various health complications, including erectile dysfunction (ED), which is more prevalent in individuals with OSA. This study explored ED in Korean OSA patients and assessed the impact of continuous positive airway pressure (CPAP) therapy on ED.

Methods: A total of 87 male patients with OSA from four different sleep centers underwent physical measurements and completed sleep and mental health (MH) questionnaires, including the Korean version of the International index of erectile function (IIEF), before and three months after initiating CPAP therapy.

Results: After three months of CPAP therapy, the patients demonstrated a significant improvement in ED as measured on the IIEF. However, the study found no significant correlation between the duration of CPAP use and the improvement in IIEF score. It did identify the SF36 quality of life assessment as a significant factor influencing ED improvement after CPAP.

Conclusions: ED is a prevalent issue that escalates with age and is associated with OSA. CPAP therapy has shown potential in alleviating ED symptoms, particularly in those with underlying psychological conditions, although further research is required to confirm these findings and understand the underlying mechanisms.

背景:阻塞性睡眠呼吸暂停(OSA)与多种健康并发症有关,其中包括勃起功能障碍(ED),而勃起功能障碍在OSA患者中更为普遍。本研究探讨了韩国 OSA 患者的勃起功能障碍问题,并评估了持续气道正压疗法(CPAP)对勃起功能障碍的影响:方法:共有 87 名来自四个不同睡眠中心的 OSA 男性患者在开始接受 CPAP 治疗前和三个月后接受了身体测量,并填写了睡眠和心理健康(MH)问卷,包括韩国版国际勃起功能指数(IIEF):结果:在使用 CPAP 治疗三个月后,根据国际勃起功能指数(IIEF)的测量结果,患者的 ED 有了明显改善。然而,研究发现使用 CPAP 的持续时间与 IIEF 分数的改善之间没有明显的相关性。研究还发现,SF36 生活质量评估是影响 CPAP 治疗后 ED 改善的一个重要因素:ED是一个普遍问题,随着年龄的增长而加剧,并与OSA有关。CPAP疗法在缓解ED症状方面具有潜力,尤其是对那些有潜在心理疾病的患者,不过还需要进一步的研究来证实这些发现并了解其潜在机制。
{"title":"Erectile dysfunction in patient with obstructive sleep apnea: effects of continuous positive airway pressure.","authors":"Hyeyun Kim, Keun Tae Kim, Won Chul Shin, Kwang Ik Yang, Ji Yong Ha, Yong Won Cho","doi":"10.1080/13685538.2024.2317165","DOIUrl":"10.1080/13685538.2024.2317165","url":null,"abstract":"<p><strong>Background: </strong>Obstructive sleep apnea (OSA) is linked to various health complications, including erectile dysfunction (ED), which is more prevalent in individuals with OSA. This study explored ED in Korean OSA patients and assessed the impact of continuous positive airway pressure (CPAP) therapy on ED.</p><p><strong>Methods: </strong>A total of 87 male patients with OSA from four different sleep centers underwent physical measurements and completed sleep and mental health (MH) questionnaires, including the Korean version of the International index of erectile function (IIEF), before and three months after initiating CPAP therapy.</p><p><strong>Results: </strong>After three months of CPAP therapy, the patients demonstrated a significant improvement in ED as measured on the IIEF. However, the study found no significant correlation between the duration of CPAP use and the improvement in IIEF score. It did identify the SF36 quality of life assessment as a significant factor influencing ED improvement after CPAP.</p><p><strong>Conclusions: </strong>ED is a prevalent issue that escalates with age and is associated with OSA. CPAP therapy has shown potential in alleviating ED symptoms, particularly in those with underlying psychological conditions, although further research is required to confirm these findings and understand the underlying mechanisms.</p>","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139934389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel perspectives of testosterone therapy in men with functional hypogonadism: traversing the gaps of knowledge. 功能性性腺功能减退症男性睾酮治疗的新视角:跨越知识鸿沟。
IF 2.6 4区 医学 Q2 Medicine Pub Date : 2024-12-01 Epub Date: 2023-12-27 DOI: 10.1080/13685538.2023.2296460
Kristina Groti Antonič, Michael Zitzmann

Introduction: In the past decade, there has been a significant augmentation in the corpus of evidence pertaining to functional hypogonadism. Despite this, prevailing clinical guidelines continue to advise against the universal screening for hypogonadism in middle-aged and elderly males.

Findings: Numerous randomized controlled trials have scrutinized the effects of testosterone therapy in males afflicted with type 2 diabetes and/or obesity. However, these guidelines uniformly assert that lifestyle modifications and weight reduction should be the primary intervention strategies in overweight and obese males, relegating testosterone therapy to a secondary, selective option. It is extensively documented that testosterone therapy can yield substantial improvements in various metabolic parameters as well as ameliorate symptoms of erectile dysfunction. Moreover, recent studies have demonstrated the potential of testosterone therapy in reversing type 2 diabetes in males with low-normal testosterone levels who are at elevated risk for this condition, in comparison to the outcomes achievable through lifestyle modifications alone.

Conclusion: This focused review article aims to present a comprehensive update on the latest data concerning the innovative aspects of testosterone therapy in males with functional hypogonadism, particularly in the context of type 2 diabetes and/or obesity. Additionally, it will delve into the cardiovascular safety of such interventions within this high-risk demographic, with a special emphasis on insights gleaned from the TRAVERSE trial.

导言:在过去十年中,有关功能性性腺功能减退症的证据显著增加。尽管如此,现行的临床指南仍然建议不要对中老年男性进行性腺功能减退症的普遍筛查:许多随机对照试验都仔细研究了睾酮疗法对患有 2 型糖尿病和/或肥胖症的男性的影响。然而,这些指南一致认为,对于超重和肥胖的男性来说,改变生活方式和减轻体重应作为主要的干预策略,而睾酮疗法只是次要的、有选择性的选择。大量资料表明,睾酮疗法可以显著改善各种代谢参数,并改善勃起功能障碍的症状。此外,最近的研究表明,与仅通过改变生活方式所能达到的效果相比,睾酮疗法在逆转睾酮水平正常但 2 型糖尿病风险较高的男性 2 型糖尿病方面具有潜力:这篇重点综述文章旨在全面更新有关功能性性腺功能减退症男性患者睾酮疗法创新方面的最新数据,尤其是在 2 型糖尿病和/或肥胖症的背景下。此外,文章还将深入探讨此类干预措施在这一高风险人群中的心血管安全性,并特别强调从 TRAVERSE 试验中获得的启示。
{"title":"Novel perspectives of testosterone therapy in men with functional hypogonadism: traversing the gaps of knowledge.","authors":"Kristina Groti Antonič, Michael Zitzmann","doi":"10.1080/13685538.2023.2296460","DOIUrl":"10.1080/13685538.2023.2296460","url":null,"abstract":"<p><strong>Introduction: </strong>In the past decade, there has been a significant augmentation in the corpus of evidence pertaining to functional hypogonadism. Despite this, prevailing clinical guidelines continue to advise against the universal screening for hypogonadism in middle-aged and elderly males.</p><p><strong>Findings: </strong>Numerous randomized controlled trials have scrutinized the effects of testosterone therapy in males afflicted with type 2 diabetes and/or obesity. However, these guidelines uniformly assert that lifestyle modifications and weight reduction should be the primary intervention strategies in overweight and obese males, relegating testosterone therapy to a secondary, selective option. It is extensively documented that testosterone therapy can yield substantial improvements in various metabolic parameters as well as ameliorate symptoms of erectile dysfunction. Moreover, recent studies have demonstrated the potential of testosterone therapy in reversing type 2 diabetes in males with low-normal testosterone levels who are at elevated risk for this condition, in comparison to the outcomes achievable through lifestyle modifications alone.</p><p><strong>Conclusion: </strong>This focused review article aims to present a comprehensive update on the latest data concerning the innovative aspects of testosterone therapy in males with functional hypogonadism, particularly in the context of type 2 diabetes and/or obesity. Additionally, it will delve into the cardiovascular safety of such interventions within this high-risk demographic, with a special emphasis on insights gleaned from the TRAVERSE trial.</p>","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139040970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical practice of the transrectal shear-wave elastography in benign prostatic hyperplasia. 良性前列腺增生症经直肠剪切波弹性成像的临床实践。
IF 2.6 4区 医学 Q2 Medicine Pub Date : 2024-12-01 Epub Date: 2024-06-12 DOI: 10.1080/13685538.2024.2363267
Xuhui Zhang, Zeyu Chen, Jia You, Qiang Lu, Liangren Liu, Diming Cai

Objective: To investigate the practical value of the transrectal two-dimensional shear-wave elastography (SWE) in benign prostatic hyperplasia (BPH).

Methods: Consecutive male participants with and without BPH constituted the BPH and control group respectively were enrolled prospectively between March and December 2022. Transrectal conventional ultrasound and SWE examinations for the prostate were performed on these participants. Data of quantitative stiffness of the transitional zone (TZ) and peripheral zone (PZ) of prostate, volume of prostate (VP) and volume of TZ (VTZ) and prostate specific androgen (PSA), etc., were collected. Linear regression analyses were used to investigate the associations between quantitative stiffness data and other clinical parameters.

Results: There were 200 participants evaluated, including 100 healthy participants and 100 BPH patients. For every one-year increment in age, it was correlated with 0.50 kPa increasement of TZ stiffness. VP and VTZ were correlated with TZ stiffness. Higher TZ stiffness was associated with higher free prostate specific antigen (PSA) and total PSA.

Conclusions: The prostate is stiffer and larger in BPH group compared to control group. Quantitative stiffness of the TZ was related with age, VP, VTZ and PSA.

目的研究经直肠二维剪切波弹性成像(SWE)在良性前列腺增生症(BPH)中的实用价值:方法:2022年3月至12月期间,连续招募患有和未患有良性前列腺增生症的男性患者,分别组成良性前列腺增生症组和对照组。对这些参与者进行了经直肠传统超声波和前列腺特异性超声波检查。收集了前列腺过渡区(TZ)和外周区(PZ)的定量硬度、前列腺体积(VP)和TZ体积(VTZ)以及前列腺特异性雄激素(PSA)等数据。采用线性回归分析研究定量硬度数据与其他临床参数之间的关联:共评估了 200 名参与者,包括 100 名健康参与者和 100 名良性前列腺增生症患者。年龄每增加一年,TZ 硬度就会增加 0.50 kPa。VP 和 VTZ 与 TZ 硬度相关。TZ硬度越高,游离前列腺特异抗原(PSA)和总PSA越高:结论:与对照组相比,良性前列腺增生组的前列腺更硬、更大。TZ的定量硬度与年龄、VP、VTZ和PSA有关。
{"title":"Clinical practice of the transrectal shear-wave elastography in benign prostatic hyperplasia.","authors":"Xuhui Zhang, Zeyu Chen, Jia You, Qiang Lu, Liangren Liu, Diming Cai","doi":"10.1080/13685538.2024.2363267","DOIUrl":"https://doi.org/10.1080/13685538.2024.2363267","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the practical value of the transrectal two-dimensional shear-wave elastography (SWE) in benign prostatic hyperplasia (BPH).</p><p><strong>Methods: </strong>Consecutive male participants with and without BPH constituted the BPH and control group respectively were enrolled prospectively between March and December 2022. Transrectal conventional ultrasound and SWE examinations for the prostate were performed on these participants. Data of quantitative stiffness of the transitional zone (TZ) and peripheral zone (PZ) of prostate, volume of prostate (VP) and volume of TZ (VTZ) and prostate specific androgen (PSA), etc., were collected. Linear regression analyses were used to investigate the associations between quantitative stiffness data and other clinical parameters.</p><p><strong>Results: </strong>There were 200 participants evaluated, including 100 healthy participants and 100 BPH patients. For every one-year increment in age, it was correlated with 0.50 kPa increasement of TZ stiffness. VP and VTZ were correlated with TZ stiffness. Higher TZ stiffness was associated with higher free prostate specific antigen (PSA) and total PSA.</p><p><strong>Conclusions: </strong>The prostate is stiffer and larger in BPH group compared to control group. Quantitative stiffness of the TZ was related with age, VP, VTZ and PSA.</p>","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141312388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Testosterone therapy over 60 months improves aging male symptoms scores in all men with adult-onset testosterone deficiency. 超过 60 个月的睾酮治疗可改善所有成年男性睾酮缺乏症患者的老年男性症状评分。
IF 2.6 4区 医学 Q2 Medicine Pub Date : 2024-12-01 Epub Date: 2024-05-29 DOI: 10.1080/13685538.2024.2357548
Karim Sultan Haider, Michael Zitzmann, Pravinath Ramachandran, Carola S König, Geoffrey Hackett, Ahmad Haider, Farid Saad, Pieter Desnerck, Richard Strange, Amar Mann, Sudarshan Ramachandran

Objective: We evaluated change (Δ) in AMSS in men with adult-onset testosterone deficiency (TD) on/not on testosterone undecanoate (TU) by analysing a registry of men with adult-onset TD.

Methods: Analyses were performed using non-parametric statistics to determine ΔAMSS at 6-12 monthly intervals in men on/not on TU and movement in AMSS. Factors predicting ΔAMSS were established via linear/multiple regression.

Results: TU was significantly associated with lower AMSS values compared with that at baseline/prior assessment during the initial 42 months treatment; 259 of the 260 men showed improvement. In the 361 men not on TU, AMSS values increased during 60 months of follow-up compared with that at baseline/prior assessment; improvement after 60 months was evident in 1 man, whilst AMSS remained the same or worsened in 213 and 147 men, respectively. In men on TU, baseline AMSS was inversely associated with ΔAMSS (R2 = 0.97), with no other factors reaching significance. Baseline AMSS, age, serum total testosterone (TT), waist circumference (WC), and diastolic blood pressure (BP) were associated with ΔAMSS in men not on TU.

Discussion: We show that TU was associated with lower AMSS in men with adult-onset TD whilst non-treatment led to increased values. Baseline AMSS values inversely predicted ΔAMSS in both groups.

目的:我们通过分析成人睾酮缺乏症(TD)患者的登记资料,评估了服用/未服用十一酸睾酮(TU)的成人睾酮缺乏症(TD)男性的 AMSS 变化(Δ):采用非参数统计法进行分析,以确定服用/未服用 TU 的男性在 6-12 个月间隔期间的 ΔAMSS 以及 AMSS 的变化情况。通过线性/多元回归确定了预测ΔAMSS的因素:在最初 42 个月的治疗中,与基线/评估前相比,服用 TU 与 AMSS 值的降低有明显关系;260 名男性中有 259 人的情况有所改善。在 361 名未服用 TU 的男性中,60 个月的随访期间,AMSS 值与基线/先前评估值相比有所上升;1 名男性在 60 个月后明显好转,而分别有 213 名和 147 名男性的 AMSS 值保持不变或恶化。在服用 TU 的男性中,基线 AMSS 与 ΔAMSS 成反比(R2 = 0.97),其他因素均不显著。在未服用 TU 的男性中,基线 AMSS、年龄、血清总睾酮(TT)、腰围(WC)和舒张压(BP)与ΔAMSS 相关:讨论:我们的研究表明,TU 与成年 TD 男性患者的 AMSS 值降低有关,而不治疗则会导致 AMSS 值升高。两组患者的AMSS基线值都与ΔAMSS呈反向预测关系。
{"title":"Testosterone therapy over 60 months improves aging male symptoms scores in all men with adult-onset testosterone deficiency.","authors":"Karim Sultan Haider, Michael Zitzmann, Pravinath Ramachandran, Carola S König, Geoffrey Hackett, Ahmad Haider, Farid Saad, Pieter Desnerck, Richard Strange, Amar Mann, Sudarshan Ramachandran","doi":"10.1080/13685538.2024.2357548","DOIUrl":"https://doi.org/10.1080/13685538.2024.2357548","url":null,"abstract":"<p><strong>Objective: </strong>We evaluated change (Δ) in AMSS in men with adult-onset testosterone deficiency (TD) on/not on testosterone undecanoate (TU) by analysing a registry of men with adult-onset TD.</p><p><strong>Methods: </strong>Analyses were performed using non-parametric statistics to determine ΔAMSS at 6-12 monthly intervals in men on/not on TU and movement in AMSS. Factors predicting ΔAMSS were established <i>via</i> linear/multiple regression.</p><p><strong>Results: </strong>TU was significantly associated with lower AMSS values compared with that at baseline/prior assessment during the initial 42 months treatment; 259 of the 260 men showed improvement. In the 361 men not on TU, AMSS values increased during 60 months of follow-up compared with that at baseline/prior assessment; improvement after 60 months was evident in 1 man, whilst AMSS remained the same or worsened in 213 and 147 men, respectively. In men on TU, baseline AMSS was inversely associated with ΔAMSS (<i>R</i><sup>2</sup> = 0.97), with no other factors reaching significance. Baseline AMSS, age, serum total testosterone (TT), waist circumference (WC), and diastolic blood pressure (BP) were associated with ΔAMSS in men not on TU.</p><p><strong>Discussion: </strong>We show that TU was associated with lower AMSS in men with adult-onset TD whilst non-treatment led to increased values. Baseline AMSS values inversely predicted ΔAMSS in both groups.</p>","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The efficacy of platelet rich plasma in the treatment of erectile dysfunction: a systematic review and meta-analysis of randomized controlled trials. 富血小板血浆治疗勃起功能障碍的疗效:随机对照试验的系统回顾和荟萃分析。
IF 2.6 4区 医学 Q2 Medicine Pub Date : 2024-12-01 Epub Date: 2024-06-04 DOI: 10.1080/13685538.2024.2358944
Qiancheng Mao, Yingying Yang, Yang Liu, Hongquan Liu, Gonglin Tang, Xiaofeng Wang, Yuanshan Cui, Jitao Wu

Background: Erectile dysfunction (ED) is a common issue among males, and the use of platelet-rich plasma (PRP) therapy for treating ED has gained increasing attention, but there is still no conclusive evidence regarding its efficacy.

Aim: To evaluate the efficacy of PRP therapy for ED.

Methods: We systematically searched PubMed, Embase, Cochrane Library, and Web of Science databases up to November 2023 to identify randomized controlled trials (RCTs) on PRP therapy for ED. We used Review Manager version 5.4 for data analysis and management.

Result: After applying inclusion and exclusion criteria for screening, a total of 4 studies involving 413 patients were finally included in our meta-analysis. According to our analysis, the PRP group showed significant advantages over the placebo group in terms of MCID at the first month (p = 0.03) and sixth months (p = 0.008), while there was no significant difference between the two groups at the third month (p = 0.19). Additionally, in terms of IIEF, PRP showed significantly better efficacy than placebo at the first, third, and sixth months (p < 0.00001).

Conclusions: PRP shows more effectiveness in treating ED compared to placebo, offering hope as a potential alternative treatment for ED.

背景:勃起功能障碍(ED)是男性的常见问题,使用富血小板血浆(PRP)疗法治疗ED已受到越来越多的关注,但关于其疗效仍没有确凿的证据:我们系统地检索了截至 2023 年 11 月的 PubMed、Embase、Cochrane Library 和 Web of Science 数据库,以确定 PRP 治疗 ED 的随机对照试验 (RCT)。我们使用Review Manager 5.4版本进行数据分析和管理:结果:在采用纳入和排除标准进行筛选后,我们的荟萃分析最终纳入了共 4 项研究,涉及 413 名患者。根据我们的分析,在第一个月(p = 0.03)和第六个月(p = 0.008)的 MCID 方面,PRP 组比安慰剂组有显著优势,而在第三个月(p = 0.19),两组之间没有显著差异。此外,在 IIEF 方面,PRP 在第一个月、第三个月和第六个月的疗效明显优于安慰剂(p 结论:PRP 对治疗男性性功能障碍更有效:与安慰剂相比,PRP 在治疗 ED 方面更有效,有望成为 ED 的一种潜在替代疗法。
{"title":"The efficacy of platelet rich plasma in the treatment of erectile dysfunction: a systematic review and meta-analysis of randomized controlled trials.","authors":"Qiancheng Mao, Yingying Yang, Yang Liu, Hongquan Liu, Gonglin Tang, Xiaofeng Wang, Yuanshan Cui, Jitao Wu","doi":"10.1080/13685538.2024.2358944","DOIUrl":"10.1080/13685538.2024.2358944","url":null,"abstract":"<p><strong>Background: </strong>Erectile dysfunction (ED) is a common issue among males, and the use of platelet-rich plasma (PRP) therapy for treating ED has gained increasing attention, but there is still no conclusive evidence regarding its efficacy.</p><p><strong>Aim: </strong>To evaluate the efficacy of PRP therapy for ED.</p><p><strong>Methods: </strong>We systematically searched PubMed, Embase, Cochrane Library, and Web of Science databases up to November 2023 to identify randomized controlled trials (RCTs) on PRP therapy for ED. We used Review Manager version 5.4 for data analysis and management.</p><p><strong>Result: </strong>After applying inclusion and exclusion criteria for screening, a total of 4 studies involving 413 patients were finally included in our meta-analysis. According to our analysis, the PRP group showed significant advantages over the placebo group in terms of MCID at the first month (<i>p</i> = 0.03) and sixth months (<i>p</i> = 0.008), while there was no significant difference between the two groups at the third month (<i>p</i> = 0.19). Additionally, in terms of IIEF, PRP showed significantly better efficacy than placebo at the first, third, and sixth months (<i>p</i> < 0.00001).</p><p><strong>Conclusions: </strong>PRP shows more effectiveness in treating ED compared to placebo, offering hope as a potential alternative treatment for ED.</p>","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141238632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolving horizons in renal angiomyolipoma: two decades of management strategies and clinical perspectives in a single institutional study. 肾血管肌脂肪瘤的发展前景:一项单一机构研究中二十年的管理策略和临床观点。
IF 2.6 4区 医学 Q2 Medicine Pub Date : 2024-12-01 Epub Date: 2024-05-06 DOI: 10.1080/13685538.2024.2346308
Ahmet Keles, Ayberk Iplikci, Ozgur Arikan, Meftun Culpan, Kursad Nuri Baydili, Ferhat Keser, Asif Yildirim

Objective: To assess various management options for renal angiomyolipoma (AML) to guide clinical practice.

Methods: A single center retrospectively reviewed an AML series from 2002 to 2022. The image reports and chart reviews of patients who received two abdominal scans at least 6 months between the first and last scans were assessed.

Results: A total of 203 patients with 209 tumors were identified and followed up for a median of 42.6 months. Active surveillance (AS) was the most frequently selected option (70.9% of cases). Interventions were required for 59 AMLs, of which 20 were treated with embolization, 29 with partial nephrectomy, 9 with radical nephrectomy, and 1 with radiofrequency (RF) ablation. The median size of the lesions at intervention was 5 cm. The average growth rate of the lesions was 0.12 cm/year, and there was a significant difference in the average growth rate of lesions ≤4 cm and those >4 cm (0.11 vs. 0.24 cm/year; p = 0.0046).

Conclusion: This series on AMLs confirms that lesions >4 cm do not require early intervention based on size alone. Appropriately selected cases of renal AML can be managed by AS.KEYWORDS: Angiomyolipoma; active surveillance; embolization; nephrectomy; nephron-sparing surgery.

目的:评估肾血管瘤(AML)的各种治疗方案,为临床实践提供指导:评估肾血管脂肪瘤(AML)的各种治疗方案,以指导临床实践:单个中心回顾性分析了2002年至2022年的AML系列。评估了接受两次腹部扫描的患者的图像报告和病历回顾,第一次扫描和最后一次扫描之间的间隔时间至少为 6 个月:结果:共发现203名患者,209个肿瘤,随访时间中位数为42.6个月。主动监测(AS)是最常见的选择(70.9%的病例)。59例急性髓系白血病需要介入治疗,其中20例采用栓塞治疗,29例采用肾部分切除术,9例采用根治性肾切除术,1例采用射频消融术。介入治疗时病灶的中位尺寸为 5 厘米。病变的平均生长速度为 0.12 厘米/年,≤4 厘米和大于 4 厘米的病变平均生长速度存在显著差异(0.11 vs. 0.24 厘米/年;P = 0.0046):本系列急性髓系白血病病例证实,>4 厘米的病变不需要仅根据大小进行早期干预。关键字:血管肌脂肪瘤;主动监测;栓塞;肾切除术;保肾手术。
{"title":"Evolving horizons in renal angiomyolipoma: two decades of management strategies and clinical perspectives in a single institutional study.","authors":"Ahmet Keles, Ayberk Iplikci, Ozgur Arikan, Meftun Culpan, Kursad Nuri Baydili, Ferhat Keser, Asif Yildirim","doi":"10.1080/13685538.2024.2346308","DOIUrl":"https://doi.org/10.1080/13685538.2024.2346308","url":null,"abstract":"<p><strong>Objective: </strong>To assess various management options for renal angiomyolipoma (AML) to guide clinical practice.</p><p><strong>Methods: </strong>A single center retrospectively reviewed an AML series from 2002 to 2022. The image reports and chart reviews of patients who received two abdominal scans at least 6 months between the first and last scans were assessed.</p><p><strong>Results: </strong>A total of 203 patients with 209 tumors were identified and followed up for a median of 42.6 months. Active surveillance (AS) was the most frequently selected option (70.9% of cases). Interventions were required for 59 AMLs, of which 20 were treated with embolization, 29 with partial nephrectomy, 9 with radical nephrectomy, and 1 with radiofrequency (RF) ablation. The median size of the lesions at intervention was 5 cm. The average growth rate of the lesions was 0.12 cm/year, and there was a significant difference in the average growth rate of lesions ≤4 cm and those >4 cm (0.11 <i>vs.</i> 0.24 cm/year; <i>p</i> = 0.0046).</p><p><strong>Conclusion: </strong>This series on AMLs confirms that lesions >4 cm do not require early intervention based on size alone. Appropriately selected cases of renal AML can be managed by AS.KEYWORDS: Angiomyolipoma; active surveillance; embolization; nephrectomy; nephron-sparing surgery.</p>","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Needs assessment survey among healthcare professionals to implement the 4Ms framework: a cross-sectional study from Qatar. 医疗保健专业人员实施 4Ms 框架的需求评估调查:来自卡塔尔的横断面研究。
IF 2.7 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-09-28 DOI: 10.1080/13685538.2024.2401161
Hanadi Al Hamad, Sameer Acharath Valappil, Brijesh Sathian

Background: Worldwide, the evidence-based 4Ms framework of the Age-Friendly Health System (AFHS) improves the experience of caring for older adults. This study aimed to examine healthcare professionals' perceptions, attitudes, and behaviors regarding the AFHS and 4Ms before they were implemented.

Methods: This study was a questionnaire-based survey of 252 healthcare professionals in geriatrics and long-term care departments, Rumailah Hospital, Acute Care Services in Hamad General Hospital, and home healthcare services to assess their perceptions, attitudes, and behaviors regarding 4Ms from November 1, 2022, to July 31, 2023.

Results: Most respondents acknowledged the benefits of providing care through AFHS. However, only 62% of respondents reported using the 4Ms framework. The most commonly used types of age-friendly care provided by health care professionals were reviews of high-risk medication use (64.2%) and screening for mobility limitations (55.8%).

Conclusion: The findings suggest that there is a need for more training and education regarding the 4Ms framework for health care providers. This training should focus on specific aspects of the framework, such as how to assess what matters most to older adults; how to manage their mobility, mentation, and medication; and how to coordinate care across settings.

背景:在全球范围内,以证据为基础的 "老年友好健康系统"(AFHS)的 4Ms 框架改善了老年人的护理体验。本研究旨在考察医护专业人员在实施 AFHS 和 4Ms 之前对其的看法、态度和行为:本研究采用问卷调查的方式,从 2022 年 11 月 1 日至 2023 年 7 月 31 日对鲁迈拉医院老年病科和长期护理部、哈马德总医院急症护理服务部以及家庭医疗服务部的 252 名医护专业人员进行了调查,以评估他们对 4Ms 的看法、态度和行为:大多数受访者承认通过家庭医疗服务提供医疗服务的好处。然而,只有 62% 的受访者表示使用了 4Ms 框架。医护人员最常用的老年友好型护理类型是审查高风险用药(64.2%)和筛查行动不便(55.8%):研究结果表明,有必要对医护人员进行更多有关 4Ms 框架的培训和教育。培训应侧重于该框架的具体方面,如如何评估对老年人最重要的事项;如何管理老年人的行动能力、精神状态和用药;以及如何协调不同环境下的护理。
{"title":"Needs assessment survey among healthcare professionals to implement the 4Ms framework: a cross-sectional study from Qatar.","authors":"Hanadi Al Hamad, Sameer Acharath Valappil, Brijesh Sathian","doi":"10.1080/13685538.2024.2401161","DOIUrl":"https://doi.org/10.1080/13685538.2024.2401161","url":null,"abstract":"<p><strong>Background: </strong>Worldwide, the evidence-based 4Ms framework of the Age-Friendly Health System (AFHS) improves the experience of caring for older adults. This study aimed to examine healthcare professionals' perceptions, attitudes, and behaviors regarding the AFHS and 4Ms before they were implemented.</p><p><strong>Methods: </strong>This study was a questionnaire-based survey of 252 healthcare professionals in geriatrics and long-term care departments, Rumailah Hospital, Acute Care Services in Hamad General Hospital, and home healthcare services to assess their perceptions, attitudes, and behaviors regarding 4Ms from November 1, 2022, to July 31, 2023.</p><p><strong>Results: </strong>Most respondents acknowledged the benefits of providing care through AFHS. However, only 62% of respondents reported using the 4Ms framework. The most commonly used types of age-friendly care provided by health care professionals were reviews of high-risk medication use (64.2%) and screening for mobility limitations (55.8%).</p><p><strong>Conclusion: </strong>The findings suggest that there is a need for more training and education regarding the 4Ms framework for health care providers. This training should focus on specific aspects of the framework, such as how to assess what matters most to older adults; how to manage their mobility, mentation, and medication; and how to coordinate care across settings.</p>","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142333047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health-related quality of life of patients with prostate cancer initiating GnRH agonist therapy: the PRISME study. 开始接受 GnRH 激动剂治疗的前列腺癌患者的健康相关生活质量:PRISME 研究。
IF 2.7 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-10-04 DOI: 10.1080/13685538.2024.2406547
François Rozet, Christophe Hennequin, Pierre Mongiat-Artus, Nathalie Pello-Leprince-Ringuet, Anne-Sophie Grandoulier, Morgan Roupret

Objectives: To compare the evolution of health-related quality of life (HRQoL) over 6 months of GnRH agonist (GnRHa) therapy among age groups for patients with prostate cancer (PCa).

Patients and methods: PRISME (NCT03516110) was a non-interventional, prospective study conducted in France in patients aged ≥60 years with PCa initiating GnRHa therapy within routine care. HRQoL was evaluated at baseline and after 6 months using the EORTC quality of life in ELDerly cancer patients 14 items (QLQ-ELD14) questionnaire. Cognitive status was assessed using the Mini Mental State Examination (MMSE). Analyses of covariance compared the evolution of the change from baseline of the QLQ-ELD14 scores among age groups.

Results: 814 patients were enrolled (245, 60-70 years; 314, 70-75 years; 252, ≥75 years). Slight or no changes were observed in each QLQ-ELD14 dimension between baseline and 6 months, overall and by age. In the primary effectiveness analysis, there was no difference among age groups in the change from baseline in QLQ-ELD14 scores. Baseline cognitive status was lower in the oldest age group, but there were no changes in all age groups. As expected, sexual function declined in all age groups.

Conclusion: GnRHa therapy influence on HRQoL, cognition and sexuality appeared independent of age.

目的比较不同年龄组的前列腺癌(PCa)患者在接受 GnRH 促效剂(GnRHa)治疗 6 个月期间健康相关生活质量(HRQoL)的变化情况:PRISME (NCT03516110)是一项在法国进行的非干预性前瞻性研究,研究对象为年龄≥60岁、在常规治疗中开始接受GnRHa治疗的PCa患者。研究采用 EORTC ELDerly 癌症患者生活质量 14 项(QLQ-ELD14)问卷对基线和 6 个月后的 HRQoL 进行了评估。认知状况采用迷你精神状态检查(MMSE)进行评估。协方差分析比较了不同年龄组的 QLQ-ELD14 分数从基线开始的变化情况:结果:共有 814 名患者入选(245 人,60-70 岁;314 人,70-75 岁;252 人,≥75 岁)。从基线到 6 个月期间,QLQ-ELD14 的每个维度都有轻微变化或没有变化,总体上如此,各年龄组也是如此。在主要疗效分析中,不同年龄组的 QLQ-ELD14 分数与基线相比没有变化。最年长年龄组的基线认知状况较低,但所有年龄组均无变化。不出所料,所有年龄组的性功能都有所下降:结论:GnRHa疗法对HRQoL、认知能力和性能力的影响似乎与年龄无关。
{"title":"Health-related quality of life of patients with prostate cancer initiating GnRH agonist therapy: the PRISME study.","authors":"François Rozet, Christophe Hennequin, Pierre Mongiat-Artus, Nathalie Pello-Leprince-Ringuet, Anne-Sophie Grandoulier, Morgan Roupret","doi":"10.1080/13685538.2024.2406547","DOIUrl":"https://doi.org/10.1080/13685538.2024.2406547","url":null,"abstract":"<p><strong>Objectives: </strong>To compare the evolution of health-related quality of life (HRQoL) over 6 months of GnRH agonist (GnRHa) therapy among age groups for patients with prostate cancer (PCa).</p><p><strong>Patients and methods: </strong>PRISME (NCT03516110) was a non-interventional, prospective study conducted in France in patients aged ≥60 years with PCa initiating GnRHa therapy within routine care. HRQoL was evaluated at baseline and after 6 months using the EORTC quality of life in ELDerly cancer patients 14 items (QLQ-ELD14) questionnaire. Cognitive status was assessed using the Mini Mental State Examination (MMSE). Analyses of covariance compared the evolution of the change from baseline of the QLQ-ELD14 scores among age groups.</p><p><strong>Results: </strong>814 patients were enrolled (245, 60-70 years; 314, 70-75 years; 252, ≥75 years). Slight or no changes were observed in each QLQ-ELD14 dimension between baseline and 6 months, overall and by age. In the primary effectiveness analysis, there was no difference among age groups in the change from baseline in QLQ-ELD14 scores. Baseline cognitive status was lower in the oldest age group, but there were no changes in all age groups. As expected, sexual function declined in all age groups.</p><p><strong>Conclusion: </strong>GnRHa therapy influence on HRQoL, cognition and sexuality appeared independent of age.</p>","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association of prealbumin, transferrin, and albumin with immunosenescence among elderly males. 前白蛋白、转铁蛋白和白蛋白与老年男性免疫衰老的关系。
IF 2.6 4区 医学 Q2 Medicine Pub Date : 2024-12-01 Epub Date: 2024-02-05 DOI: 10.1080/13685538.2024.2310308
Ren-Dan Zhang, Shi-Qin Jiang, Feng-Juan Yan, Lei Ruan, Cun-Tai Zhang, Xiao-Qing Quan

Objective: As people get older, the innate and acquired immunity of the elderly are affected, resulting in immunosenescence. Prealbumin (PAB), transferrin (TRF), and albumin (ALB) are commonly used markers to monitor protein energy malnutrition (PEM). However, their relationship with the immune system has not been fully explored.

Methods: In our study, a total of 93 subjects (≥65 years) were recruited from Tongji Hospital between January 2015 and February 2017. According to the serum levels of these proteins (PAB, TRF, and ALB), we divided the patients into the high serum protein group and the low serum protein group. Then, we compared the percent expression of lymphocyte subsets between two groups.

Results: All the low serum protein groups (PAB, TRF, and ALB) had significant decreases in the percentage of CD4+ cells, CD3+CD28+ cells, CD4+CD28+ cells and significant increases in the percentage of CD8+ cells, CD8+CD28- cells. PAB, TRF, and ALB levels revealed positive correlations with CD4/CD8 ratio, proportions of CD4+ cells, CD3+CD28+ cells, CD4+CD28+ cells, and negative correlation with proportions of CD8+ cells, CD8+CD28- cells.

Conclusions: This study suggested PAB, TRF, and ALB could be used as immunosenescence indicators. PEM might accelerate the process of immunosenescence in elderly males.

目的随着年龄的增长,老年人的先天性免疫和获得性免疫都会受到影响,从而导致免疫衰老。前白蛋白(PAB)、转铁蛋白(TRF)和白蛋白(ALB)是监测蛋白质能量营养不良(PEM)的常用指标。然而,它们与免疫系统的关系尚未得到充分探讨:在我们的研究中,2015年1月至2017年2月期间,我们从同济医院共招募了93名受试者(≥65岁)。根据这些蛋白(PAB、TRF 和 ALB)的血清水平,我们将患者分为高血清蛋白组和低血清蛋白组。然后,我们比较了两组淋巴细胞亚群的表达百分比:结果:所有低血清蛋白组(PAB、TRF 和 ALB)的 CD4+ 细胞、CD3+CD28+ 细胞、CD4+CD28+ 细胞的百分比都显著下降,而 CD8+ 细胞、CD8+CD28- 细胞的百分比则显著上升。PAB、TRF和ALB水平与CD4/CD8比率、CD4+细胞比例、CD3+CD28+细胞比例、CD4+CD28+细胞比例呈正相关,与CD8+细胞比例、CD8+CD28-细胞比例呈负相关:本研究表明,PAB、TRF和ALB可作为免疫衰老指标。结论:该研究表明,PAB、TRF和ALB可作为免疫衰老的指标,PEM可能会加速老年男性的免疫衰老过程。
{"title":"The association of prealbumin, transferrin, and albumin with immunosenescence among elderly males.","authors":"Ren-Dan Zhang, Shi-Qin Jiang, Feng-Juan Yan, Lei Ruan, Cun-Tai Zhang, Xiao-Qing Quan","doi":"10.1080/13685538.2024.2310308","DOIUrl":"10.1080/13685538.2024.2310308","url":null,"abstract":"<p><strong>Objective: </strong>As people get older, the innate and acquired immunity of the elderly are affected, resulting in immunosenescence. Prealbumin (PAB), transferrin (TRF), and albumin (ALB) are commonly used markers to monitor protein energy malnutrition (PEM). However, their relationship with the immune system has not been fully explored.</p><p><strong>Methods: </strong>In our study, a total of 93 subjects (≥65 years) were recruited from Tongji Hospital between January 2015 and February 2017. According to the serum levels of these proteins (PAB, TRF, and ALB), we divided the patients into the high serum protein group and the low serum protein group. Then, we compared the percent expression of lymphocyte subsets between two groups.</p><p><strong>Results: </strong>All the low serum protein groups (PAB, TRF, and ALB) had significant decreases in the percentage of CD4+ cells, CD3<sup>+</sup>CD28<sup>+</sup> cells, CD4<sup>+</sup>CD28<sup>+</sup> cells and significant increases in the percentage of CD8<sup>+</sup> cells, CD8<sup>+</sup>CD28<sup>-</sup> cells. PAB, TRF, and ALB levels revealed positive correlations with CD4/CD8 ratio, proportions of CD4<sup>+</sup> cells, CD3<sup>+</sup>CD28<sup>+</sup> cells, CD4<sup>+</sup>CD28<sup>+</sup> cells, and negative correlation with proportions of CD8<sup>+</sup> cells, CD8<sup>+</sup>CD28<sup>-</sup> cells.</p><p><strong>Conclusions: </strong>This study suggested PAB, TRF, and ALB could be used as immunosenescence indicators. PEM might accelerate the process of immunosenescence in elderly males.</p>","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Aging Male
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1